? There are many clinical studies directly demonstrating the importance of hypoxia in limiting the response to essentially all forms of cancer therapy. Additionally, hypoxia is thought to affect the very nature of cancer, with hypoxic tumors being more susceptible to genetic instability and aggressive phenotypes. At present, it is not known whether hypoxia is simply associated with aggressive tumors, or whether it is the driving force. There has been a great interest in the development of methods to image clinically relevant tumor hypoxia by non-invasive means. In this Application we will employ a 2-nitroimidazole hypoxia marker, EF5, for this purpose. EF5 is unique because its oxygen-dependent bioreduction can be studied in two distinct ways: first; highly specific antibodies can be used for quantitative immunohistochemical detection at sub-cellular resolution (e.g. fluorescence microscopy of tissue sections or flow cytometric analysis) and secondly; non-invasive imaging using F-18-1abeled drug. Both methods have been shown to correlate with individual-tumor radiation-response prediction in the 9L gliosarcoma rat-tumor-model. Using this model, three hypotheses will be tested (a fourth will employ the HTIOB0 human sarcoma xenograft):
The first aim will test the hypothesis that moderate to high concentrations of hypoxia markers are necessary to promote optimal prediction of tissue hypoxia. This represents a continuation of our prior grant and requires the engineering of an innovative method (developed by Dr. Olof Solin in Finland) to produce high specific activity fluorine gas (not possible with normal techniques). The technology developed in this aim will benefit planned human studies, and allow new methods for labeling compounds with radioactive fluorine.
The second Aim will compare the now validated radiation response prediction of EF5 with two other clinically relevant techniques: uptake of labeled Cu-ATSM and interstitial fluid pressure. The goal in this aim is to assess whether the various predictive assays are truly monitoring hypoxia, or other relevant resistance factors. The 3rd Aim will test the clinically relevant hypothesis that F-18-EF5 imaging can detect intra-tumoral changes in radiation resistance caused by heterogeneity in the spatial distribution of hypoxia. Success of this Aim could lead to important new uses of therapies such as IMRT and proton beams which can be directed to spatial locations of one cc or so.
Our final Aim, to be studied in the HT1080 human sarcoma xenograft, will test the hypothesis that F-18-EF5 imaging can monitor microenvironmental changes caused by antivascular and antiangiogenic therapies. In summary, the aims of this grant will extend and advance our overall laboratory interest in quantifying the degree and extent of clinically relevant hypoxia in the tumor microenvironment. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA087645-05
Application #
6873865
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Croft, Barbara
Project Start
2000-07-01
Project End
2010-02-28
Budget Start
2005-03-07
Budget End
2006-02-28
Support Year
5
Fiscal Year
2005
Total Cost
$368,776
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Koch, Cameron J; Evans, Sydney M (2015) Optimizing hypoxia detection and treatment strategies. Semin Nucl Med 45:163-76
Busch, Theresa M (2010) Hypoxia and perfusion labeling during photodynamic therapy. Methods Mol Biol 635:107-20
Koch, Cameron J; Scheuermann, Joshua S; Divgi, Chaitanya et al. (2010) Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 37:2048-59
Kachur, Alexander V; Dolbier Jr, William R; Xu, Wei et al. (2010) Catalysis of fluorine addition to double bond: an improvement of method for synthesis of (18)F PET agents. Appl Radiat Isot 68:293-6
Koch, Cameron J; Shuman, Anne L; Jenkins, Walter T et al. (2009) The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 85:1137-47
Evans, Sydney M; Jenkins, Kevin W; Jenkins, W Timothy et al. (2008) Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiat Res 170:677-90
Koch, Cameron J; Evans, Sydney M (2003) Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 510:285-92